137 results on '"KAYMAKOĞLU, SABAHATTİN"'
Search Results
102. Combined or monotherapy, which is better in antiHBe (+) chronic hepatitis B?
- Author
-
Danalioglu, Ahmet, Kaymakoglu, Sabahattin, Cakaloglu, Yilmaz, Demir, Kadir, Akyuz, Filiz, Aksoy, Nevzat, Poturoglu, Sule, Turkoglu, Salih, Badur, Selim, Besisik, Fatih, Okten, Atilla, and Ak, Nevzat
- Published
- 2003
- Full Text
- View/download PDF
103. The efficacy of interferon-μ induction treatment with or without ribavirin in chronic hepatitis C: Interim analysis
- Author
-
Senturk, Hakan, Ersoz, Galip, Ozaras, Resat, Kaymakoglu, Sabahattin, Bozkaya, Hakan, Mert, Ali, Karayalcin, Selim, Bozdayi, Mithat, and Batur, Yucel
- Published
- 2001
- Full Text
- View/download PDF
104. Helicobacter pylori eradication lowers esophageal sphincter pressures in non-ulcer dispepsia patients
- Author
-
Besisik, Fatih S., Sutucu, Filiz, Dincer, Dine, Kaplan, Yersu, Arici, Serpil, Menda, Yusuf, Demir, Kadir, Kaymakoglu, Sabahattin, and Mungan, Zeynel
- Published
- 2000
- Full Text
- View/download PDF
105. The prevalence of manifest and latent gluten sensitive enteropathy in insulin dependent diabetes mellitus
- Author
-
Guvenc, Serkan, Kaymakoglu, Sabahattin, Polat, Nuray Gurel, Karsidag, Kubilay, Demir, Kadir, Dincer, Dinc, Cekik, Cigdem, Salman, Serpil, Yilmaz, Temel, Besisikr, Fatih, and Cakaloglu, Yilmaz
- Published
- 2000
- Full Text
- View/download PDF
106. Intestinal metaplasia of the gastric cardia in a country with high Helicobacter pylori prevalance
- Author
-
Dincer, Dine, Besisik, Fatih S., Cevikbas, Ugur, Kaymakoglu, Sabahattin, Demir, Kadir, and Mungan, Zeynel
- Published
- 2000
- Full Text
- View/download PDF
107. Hemodiyaliz Hastalarında HLA II Genlerinin Kronik C Hepatitinin İnterferon ile Tedavisinde Yanıta Etkisi.
- Author
-
Dinç, Dinçer, Fatih, Beşııık, Fatma, Oğuz, Sever, Mehmet Ş., Kaymakoğlu, Sabahattin, Çakaloğlu, Yılmaz, Demir, Kadir, Türkoğlu, Salih, Çarin, Mahmut, and Ökten, Atilla
- Published
- 1999
108. Pankreas Tümörünü Taklit Eden Bir Abdominal Tüberküloz Olgusu.
- Author
-
Demir, Kadir, Gürel, Selim, Dinçer, Dinç, Kaymakoğlu, Sabahattin, Beşışık, Fatih, Çakaloğlu, Yılmaz, Acunaş, Bülent, and Ōkten, Atilla
- Published
- 1998
109. ROLE OF THE TACROLIMUS IN POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME.
- Author
-
Orhan, Elif Kocasoy, Alpsan, Hale, Bebek, Nerses, Pınarbaşı, Binnur, Kaymakoğlu, Sabahattin, Özden, İlgin, and Çoban, Oğuzhan
- Subjects
- *
TACROLIMUS , *NEUROTOXICOLOGY , *NEUROLOGICAL disorders , *IMMUNOSUPPRESSIVE agents , *ANTICONVULSANTS , *ANTIHYPERTENSIVE agents - Abstract
Posterior reversible encephalopathy syndrome (PRES), is a group of disorders which may present with headache, seizures, visual changes, altered mental status or focal neurological deficits. Many different conditions and diseases, which include tacrolimus treatment, may cause this syndrome. We present a 55 year old woman presented with PRES possibly due to tacrolimus treatment for liver transplantation. The patient stabilized after tacrolimus dose was decreased, and antihypertensive and antiepileptic treatments were started. PRES is one of the neurological complications developing after solid organ transplantation. Early diagnosis and treatment is important for the patient's life as these patients are immunsuppressive and prone to many complications of transplantation. Here we present a case of PRES, possibly due to tacrolimus use after a living donor liver transplantation and discuss briefly the possible mechanisms of PRES. [ABSTRACT FROM AUTHOR]
- Published
- 2015
110. Horizontal transmission of hepatitis B virus infection
- Author
-
Cakaloglu, Yilmaz, Kaymakoglu, Sabahattin, Okten, Atilla, Besisik, Fatih, Badur, Selim, and Yalcin, Suleyman
- Published
- 1992
- Full Text
- View/download PDF
111. Risk factors associated with progression to intestinal complications of Crohn disease
- Author
-
Yusuf Kayar, Bulent Baran, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu, Ning-Ning Wang, Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Kayar, Yusuf, Örmeci, Aslı Çiftçibaşı, Akyuz, Filiz, Demir, Kadir, Beşışık, Fatih, Kaymakoğlu, Sabahattin, School of Medicine, and Department of Internal Diseases, Gastroenterology and Hepatology
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Perianal disease ,Location ,lcsh:Medicine ,Disease ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Risk Factors ,Internal medicine ,Disease behavior ,medicine ,Humans ,Young adult ,Proportional Hazards Models ,business.industry ,Crohn disease ,Proportional hazards model ,lcsh:R ,Smoking ,Behavior change ,Mean age ,Original Articles ,General Medicine ,medicine.disease ,Surgery ,Intestinal Diseases ,Stenosis ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,Medicine ,Female ,business ,030217 neurology & neurosurgery - Abstract
Background: crohn disease is a chronic bowel disease that causes serious complications. Prevalence of Crohn disease is increasing. Studies have shown that the behavior of the disease is not stable and severe complications secondary to behavior change over time have been shown. In this study, we aimed to evaluate the prognostic risk factors associated with phenotypic change in Crohn disease in a Turkish patient cohort. Methods: patients followed up from March 1986 to August 2011 were evaluated for demographic and clinical characteristics to determine possible risk factors and initial clinical phenotype of the disease based on the Montreal classification. The cumulative probabilities of developing stricturing or penetrating intestinal complications were estimated using the Kaplan-Meier analysis. Univariate and multivariate Cox-proportional hazard models were used to assess associations between baseline clinical characteristics and intestinal complications. Results: three hundred and thirty patients (mean age, 30.6 ± 11.1 years; 148 female) were included in the study. Mean follow-up duration was 7.4 ± 5.3 years (range: 1.0-25.0 years). At baseline 273 patients had inflammatory-type disease, 57 patients experienced stricturing/penetrating intestinal complications before or at the time of diagnosis. The cumulative probability of developing complicated disease was 37.4% at 5 years, 54.3% at 10 years, 78.8% at 25 years. Independent predictors associated with progression to intestinal complications were current smoking, perianal disease, extra-intestinal manifestations, and location of disease. Conclusions: location of disease is the most powerful indicator for the development of stenosis and penetrating complications in inflammatory-type disease. Patients with ileal involvement should be considered for more aggressive immunosuppressive therapy., NA
- Published
- 2019
112. Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers
- Author
-
Kadir Demir, Sabahattin Kaymakoglu, Bulent Baran, Fatih Besisik, Filiz Akyuz, Tahsin Ozpolat, Raim Iliaz, Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Iliaz, Raim, Özpolat, Tahsin, Demir, Kadir, Kaymakoğlu, Sabahattin, Beşışık, Fatih, Akyüz, Filiz, and Koç University Hospital
- Subjects
Adult ,Male ,medicine.medical_specialty ,Ascitic fluid infection ,Cirrhosis ,Inflammatory marker ,Mortality ,Time Factors ,Neutrophils ,Gastroenterology and hepatology ,Serum Albumin, Human ,Kaplan-Meier Estimate ,Peritonitis ,Gastroenterology ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Spontaneous bacterial peritonitis ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,medicine ,Humans ,Lymphocyte Count ,Lymphocytes ,Aged ,Hepatology ,biology ,business.industry ,Mortality rate ,C-reactive protein ,Albumin ,Case-control study ,Reproducibility of Results ,Bacterial Infections ,Middle Aged ,medicine.disease ,Prognosis ,C-Reactive Protein ,030220 oncology & carcinogenesis ,Predictive value of tests ,Case-Control Studies ,biology.protein ,030211 gastroenterology & hepatology ,Female ,Inflammation Mediators ,business ,Biomarkers ,circulatory and respiratory physiology - Abstract
Objectives: Spontaneous bacterial peritonitis (SBP) is a common and high-mortality infectious complication of patients with cirrhosis. New inflammatory markers are associated with morbidity/mortality in various diseases. The aim of our study was to find the 30-day mortality rate of SBP and their predictors. Patients and methods: Seventy patients with cirrhosis complicated with SBP and 55 non-SBP controls were enrolled into the study, and patients were evaluated for mortality rate and its predictors. Results: The 30-day and 3-month mortality rates in the SBP group were 26.1 and 50.7%, respectively. Mortality rates were higher in the SBP group than in the controls. Symptoms at hospital admission and cell counts in ascitic fluid made no difference in predicting 30-day mortality. Patients with SBP with high serum neutrophil counts, high neutrophil-lymphocyte ratio, high C reactive protein (CRP)/albumin ratio, and high model for end-stage liver disease (MELD) score had higher 30-day mortality rates. We determined optimal cutoff values of MELD scores and serum neutrophil counts for predicting 30-day mortality as 20.5 and 6850/mm(3), respectively. The sensitivity and specificity for the MELD cutoff value were 83.3 and 80.4%, respectively. We also followed up patients for 60 months after SBP; the patients with high inflammatory markers and MELD scores at the time of SBP diagnosis had worse survival compared with the group with lower levels. Conclusion: Our results suggest that SBP has high 30-day mortality. MELD scores and inflammatory markers (CRP, CRP albumin ratio, neutrophil-lymphocyte ratio) may be used to predict mortality in patients with SBP., NA
- Published
- 2018
113. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
- Author
-
Filiz Akyuz, Fatih Besisik, Arzu Poyanli, Cetin Karaca, Ozlem Mutluay Soyer, Mine Gulluoglu, Sabahattin Kaymakoglu, Omer Ekinci, Bulent Baran, Asli Ormeci, Suut Gokturk, Kadir Demir, Sami Evirgen, Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Ekinci, Ömer, Örmeci, Aslı Çifcibaşı, Soyer, Özlem Mutluay, Göktürk, Suut, Evirgen, Sami, Poyanlı, Arzu, Güllüoğlu, Mine, Akyüz, Filiz, Karaca, Çetin, Demir, Kadir, Besisik, Fatih, Kaymakoğlu, Sabahattin, and Koç University Hospital
- Subjects
medicine.medical_specialty ,Cirrhosis ,Medicine ,Gastroenterology and hepatology ,Survival ,Hepatocellular carcinoma ,Alfa-fetoprotein ,Gastroenterology ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Internal medicine ,medicine ,Retrospective Cohort Study ,Survival analysis ,Hepatology ,Proportional hazards model ,business.industry ,medicine.disease ,Prognosis ,Transplantation ,Treatment ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Liver function ,business ,Viral hepatitis - Abstract
Aim: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. Methods: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. Child-Pugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. Results: Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16 (13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size (OR = 3.19, 95% CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP (OR = 2.95, 95% CI: 1.38-6.31), total tumor diameter (OR = 3.14, 95% CI: 1.01-9.77), and hepatitis B infection (OR = 5.37, 95% CI: 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization (HR = 0.38, 95% CI: 0.28-0.51) and radioembolization (HR = 0.36, 95% CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments (log-rank, P < 0.001). Conclusion: Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma., NA
- Published
- 2018
114. A rare complication of endoscopic injection sclerotherapy: Thrombosis of subclavian vein
- Author
-
Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı., Gürel, Selim, Demir, Kadir, Kaymakoğlu, Sabahattin, Boztaş, Güngör, Çakaloğlu, Yılmaz, Beşişik, Fatih, Ökten, Atilla, AAD-9058-2020, AAT-2362-2020, and AAT-3618-2020
- Subjects
Adult ,Male ,Vein thrombosis ,Esophageal and gastric varices ,Bacteremia ,Article ,Injections ,Bleeding esophageal-varices ,Sclerotherapy ,Case report ,Humans ,Elective surgery ,Esophagus varices bleeding ,Subclavian vein ,Priority journal ,Subclavian vein thrombosis ,Hemostasis ,Sclerosis ,Prophylaxis ,Endoscopic sclerotherapy ,Esophagus Varices ,Portal Hypertension ,Varicosis ,Hemodynamics ,Endoscopy ,Thrombosis ,Endoscopic injection sclerotherapy ,Follow up ,Phlebography ,Sclerosing agent ,Surgery ,Gastroenterology & hepatology ,Human - Abstract
A 28-year-old man with compensated cirrhosis of the liver (Child B) and after 4 episodes of esophageal variceal bleeding received prophylactic endoscopic variceal sclerotherapy in our Gastroenterology Clinic for 8 consecutive months. Sclerotherapy of the esophageal varices had been performed at monthly intervals until variceal obliteration was achieved. Both the intravariceal and paravariceal injection techniques were used and injections were repeated periodically as necessary. On the 8th month, 1 week after the 4th sclerotherapy procedure, the patient complained of swelling on his right shoulder and on his right arm. There was jugular congestion and swelling of his right arm and right shoulder. The patient was hemodynamically stable. An X-ray of brachial venography revealed an obstruction of the vena subclavia dextra. During follow-up, the jugular congestion and swelling of his right arm gradually subsided spontaneously over a 6-month period without any need for medication. There has been no recurrence of his symptoms during the 1-year follow-up period. Now, he is still well clinically. This experience suggests that endoscopic injection sclerotherapy may cause thrombosis of the subclavian vein which have been never seen before.
- Published
- 2000
115. The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists.
- Author
-
Kabaçam G, Dayangaç M, Üçbilek E, Erçin CN, Günsar F, Akyıldız M, Akarsu M, Demir M, Kaymakoğlu S, Karasu Z, and İdilman R
- Subjects
- Betacoronavirus, COVID-19, Coronavirus Infections epidemiology, Coronavirus Infections virology, Humans, Liver Diseases virology, Pandemics, Pneumonia, Viral epidemiology, Pneumonia, Viral virology, SARS-CoV-2, Turkey epidemiology, Coronavirus Infections complications, Gastroenterology standards, Gastrointestinal Diseases virology, Liver Transplantation standards, Pneumonia, Viral complications, Practice Guidelines as Topic
- Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel acute infectious disease that has rapidly reached staggering pandemic proportions. This review addresses gastroenterologists, hepatologists, liver transplant (LT) specialists, and health-care professionals working in the field of liver diseases and liver transplantation. It has been written based on a limited number of publications, recommendations of national and international liver and organ transplantation societies, and experiences of patients with COVID-19 around the world. The purpose of this review is to provide information addressing questions and concerns about COVID-19, to reveal the effects of the novel disease on patients with chronic liver disease and LT recipients, and to share information about ways in which this pandemic will affect clinical practices. We, the Turkish Association for the Study of the Liver (TASL), would like to remind you that this text is actually not a practical guide. It is imperative to act according to the standards set by health-care institutions and the Ministry of Health, Republic of Turkey.
- Published
- 2020
- Full Text
- View/download PDF
116. Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?
- Author
-
İliaz R, Akyüz F, Yeğen G, Örmeci A, Göktürk S, Akyüz Ü, Baran B, Mutluay Ö, Evirgen S, Karaca Ç, Demir K, Beşışık F, Güllüoğlu M, and Kaymakoğlu S
- Subjects
- Adolescent, Adult, Aged, Biopsy, Constipation immunology, Constipation pathology, Diarrhea immunology, Diarrhea pathology, Female, Humans, Ileum pathology, Immunity, Cellular, Intestinal Mucosa pathology, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome pathology, Lymphocyte Count, Male, Middle Aged, Rectum pathology, Young Adult, Ileum immunology, Intestinal Mucosa immunology, Irritable Bowel Syndrome immunology, Rectum immunology, T-Lymphocytes metabolism
- Abstract
Background/aims: Recently, mucosal inflammation has been proposed to be one of the mechanisms underlying the pathophysiology of irritable bowel syndrome (IBS); however, there are controversial results regarding this hypotheses. Our aim was to evaluate immune cell infiltration in rectal and ileal biopsy specimens of patients with IBS and to compare it with those of healthy controls., Materials and Methods: In total, 36 patients with IBS (15 with diarrhea and 21 with constipation) and 16 healthy volunteers were enrolled. Ileocolonoscopy and ileal/rectal biopsies were performed. Rectal and terminal ileal biopsy specimens were evaluated for mucosal immune cell infiltration using immunohistochemical analysis. Serotonin positivity as well as counts of intraepithelial lymphocytes (IEL) and CD4+, CD8+, CD20+, and CD3+ cells were determined by a single pathologist who is an expert in the gastrointestinal system., Results: CD3+ and CD4+ cell counts in rectal and terminal ileal biopsy specimens were lower in the IBS group than in the controls. Conversely, there was no statistically significant difference between the IBS and control groups in terms of serotonin positivity as well as counts of IEL and CD20+ and CD8+ cells. Comparison between the IBS subgroups revealed a higher number of IEL in rectal biopsy specimens of the diarrhea dominant group. In the IBS subgroups, immune cell counts in terminal ileal and rectal biopsy specimens showed a positive correlation., Conclusion: IBS and its subgroups showed lower immune cell counts than the controls in our study. These results indicate that there is no significant mucosal inflammation in homogeneous groups of patients with IBS. Rectal biopsies may be sufficient for the evaluation of inflammation in IBS.
- Published
- 2018
- Full Text
- View/download PDF
117. Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines.
- Author
-
Yurdaydın C, Tabak F, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ, Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, and Guidelines Study Group VH
- Subjects
- Antiviral Agents standards, Antiviral Agents therapeutic use, Hepatitis Delta Virus, Humans, Interferon-alpha standards, Interferon-alpha therapeutic use, Liver Function Tests standards, Turkey, Disease Management, Hepatitis D diagnosis, Hepatitis D therapy
- Published
- 2017
- Full Text
- View/download PDF
118. Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus.
- Author
-
Idilman R, Baykam N, Kaymakoğlu S, Tabak F, Bahçecioğlu HI, Bektaş A, Bulut C, Günşar F, İnan D, Karaosmanoğlu HK, Karasu Z, Kuşçu F, Mete B, Özbakır Ö, Özdoğan OC, Parlak M, Sırmatel F, Topalak Ö, Ünsal B, and Guidelines Study Group VH
- Subjects
- Antiviral Agents standards, Antiviral Agents therapeutic use, Hepacivirus, Humans, Liver Cirrhosis virology, Liver Function Tests standards, Turkey, Disease Management, Hepatitis C
- Abstract
The present guideline updates the Turkish recommendations for the screening, diagnosis and management of Hepatitis C virus (HCV) infection prepared by the Turkish Association for the Study of the Liver (TASL) and Viral Hepatitis Society (VHS). The aim of this guidance was to provide updates recommendations to physicians, who are interested in HCV care on the optimal screening, diagnosis and pre-treatment management for patients with HCV infection in Turkey. These recommendations, produced by panel experts, were aimed to addresses the management issues ranging from diagnosis and linkage to care, to the optimal treatment regimen in patients with HCV infection. Recommendations are based on evidence and opinions of more than 70% of the panelists. This guidance is supported by the memberships of two societies and not by pharmaceutical companies. This guidance will be updated frequently as new data become available.
- Published
- 2017
- Full Text
- View/download PDF
119. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines.
- Author
-
Tabak F, Yurdaydın C, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ, Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, and Guidelines Study Group VH
- Subjects
- Hepatitis B virus, Humans, Liver Cirrhosis virology, Liver Function Tests standards, Turkey, Antiviral Agents therapeutic use, Disease Management, Hepatitis B diagnosis, Hepatitis B therapy
- Published
- 2017
- Full Text
- View/download PDF
120. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
- Author
-
Avşar E, Tiftikçi A, Poturoğlu S, Erzin Y, Kocakaya O, Dinçer D, Yıldırım B, Güliter S, Türkay C, Yılmaz U, Onuk MD, Bölükbaş C, Ellidokuz E, Bektaş A, Taşan G, Aytuğ N, Ateş Y, and Kaymakoğlu S
- Subjects
- Adolescent, Adult, Aged, Amoxicillin adverse effects, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Bismuth adverse effects, Clarithromycin administration & dosage, Clarithromycin adverse effects, Drug Administration Schedule, Drug Therapy, Combination, Dyspepsia microbiology, Endoscopy, Digestive System, Female, Helicobacter Infections diagnosis, Histamine H2 Antagonists administration & dosage, Histamine H2 Antagonists adverse effects, Humans, Lansoprazole adverse effects, Male, Middle Aged, Prospective Studies, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors adverse effects, Ranitidine administration & dosage, Ranitidine adverse effects, Treatment Outcome, Young Adult, Amoxicillin administration & dosage, Bismuth administration & dosage, Dyspepsia drug therapy, Helicobacter Infections drug therapy, Helicobacter pylori drug effects, Lansoprazole administration & dosage, Ranitidine analogs & derivatives
- Abstract
Background/aims: Proton-pump inhibitor and ranitidine bismuth citrate-based triple regimens are the two recommended first line treatments for the eradication of Helicobacter pylori. We aimed to compare the effectiveness and tolerability of these two treatments in a prospective, multicentric, randomized study., Materials and Methods: Patients with dyspeptic complaints were recruited from 15 study centers. Presence of Helicobacter pylori was investigated by both histology and rapid urease test. The patients were randomized to either ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=149) or lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=130) treatment arm for 14 days. Adverse events have been recorded during the treatment phase. A 13 C urea breath test was performed 6 weeks after termination of treatment to assess the efficacy of the therapy. Eradication rate was calculated by intention-to-treat and per-protocol analysis., Results: Two hundred seventy-nine patients (123 male, 156 female) were eligible for randomization. In per-protocol analysis (n=247), Helicobacter pylori was eradicated with ranitidine bismuth citrate- and lansoprazole-based regimens in 74,6% and 69,2% of cases, respectively (p>0,05). Intention-to-treat analysis (n=279) revealed that eradication rates were 65,1% and 63,6% in ranitidine bismuth citrate and in lansoprazole-based regimens, respectively (p>0,05). Both regimes were well-tolerated, and no serious adverse event was observed during the study., Conclusion: Ranitidine bismuth citrate-based regimen is at least as effective and tolerable as the classical proton-pump inhibitor-based regimen, but none of the therapies could achieve the recommendable eradication rate.
- Published
- 2013
- Full Text
- View/download PDF
121. Etiological factors of duodenal and gastric ulcers.
- Author
-
Uyanikoğlu A, Danalioğlu A, Akyüz F, Ermış F, Güllüoğlu M, Kapran Y, Demır K, Ozdıl S, Beşişik F, Boztaş G, Mungan Z, and Kaymakoğlu S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Antigens, Bacterial analysis, Calcium analysis, Female, Gastrins analysis, Helicobacter Infections diagnosis, Helicobacter Infections epidemiology, Helicobacter pylori immunology, Helicobacter pylori isolation & purification, Humans, Male, Middle Aged, Prospective Studies, Urease analysis, Young Adult, Duodenal Ulcer etiology, Stomach Ulcer etiology
- Abstract
Background/aims: We aimed to determine the etiology of patients with duodenal and gastric ulcers., Methods: 140 patients diagnosed with peptic ulcer between April 2002-2009 were enrolled in this prospective study. Two biopsy specimens were collected from the antrum and corpus for histology and one for rapid urease testing, and stool samples were analyzed for Helicobacter pylori antigen. Serum calcium and gastrin levels were also analyzed., Results: 82 (58%) patients were male, with a median age of 47.70±15.03 years (range: 16-92). The ulcer was located in the duodenum in 96 patients, stomach in 40, and both duodenum and stomach in 4. The rates of patients positive for Helicobacter pylori antigen in stool, positive in urease testing and positive for Helicobacter pylori presence in antral and corpus samples were 48%, 52%, 67%, and 60%, respectively. 107 (76%) patients were positive for Helicobacter pylori in one of the test methods. 64 (46%) patients had a history of nonsteroidal antiinflammatory drug use within the last month. Mean levels of calcium and gastrin were 9.29±0.40 (7.90-10.20) and 73.96±89.88 (12.86-562.50), respectively. Gastrin level was correlated to inflammatory activity (p<0.05). 19 (13.6%) of the patients were negative for Helicobacter pylori, nonsteroidal anti- inflammatory drug use and hypersecretory illness, and were classified as idiopathic., Conclusions: The most common cause of duodenal and gastric ulcer was Helicobacter pylori, and it was responsible for three-fourths of the cases. About half of the patients had a history of nonsteroidal antiinflammatory drug use, and nonsteroidal antiinflammatory drug and Helicobacter pylori were both responsible for the ulcer in three-fourths of these patients. In about one-tenth of the patients, nonsteroidal antiinflammatory drug use was the cause of ulcer alone, and about one-tenth of the ulcers were classified as idiopathic.
- Published
- 2012
- Full Text
- View/download PDF
122. Measurement of the coronary flow velocity reserve in patients with non-alcoholic fatty liver disease.
- Author
-
Pinarbaşi B, Demır K, Oflaz H, Ahishali E, Akyüz F, Elıtok A, Çımen AO, Gölcük E, Güllüoğlu M, İşsever H, Beşişik F, Kaymakoğlu S, and Ökten A
- Subjects
- Adult, Coronary Artery Disease complications, Coronary Vessels diagnostic imaging, Coronary Vessels physiology, Diastole physiology, Echocardiography, Doppler, Endothelium, Vascular physiology, Fatty Liver complications, Female, Humans, Male, Microcirculation physiology, Middle Aged, Non-alcoholic Fatty Liver Disease, Blood Flow Velocity physiology, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease physiopathology, Coronary Circulation physiology, Fatty Liver physiopathology
- Abstract
Background/aims: Endothelial dysfunction is an early and reversible feature in the pathogenesis of atherosclerosis. Coronary flow velocity reserve is a noninvasive test showing endothelial function of epicardial coronary arteries and coronary microcirculatory function. This study was designed to evaluate the carotid intima-media thickness and myocardial microvascular circulation in patients with non-alcoholic fatty liver disease., Materials and Methods: Twenty-four patients with non-alcoholic fatty liver disease and 28 healthy subjects were studied. According to the pathology of liver biopsies, patients with non-alcoholic fatty liver disease were divided into non-alcoholic fatty liver and nonalcoholic steatohepatitis groups. Coronary diastolic peak flow velocities were measured at baseline, and then dipyridamole infusion was measured by transthoracic Doppler echocardiography. The ratio of hyperemic to baseline diastolic peak velocities was calculated and the intima-media thicknesss of the carotid arteries were measured., Results: Baseline average diastolic peak and diastolic mean flow velocities were similar between non-alcoholic fatty liver disease patients and healthy subjects. However, hyperemic average diastolic peak and diastolic mean flow velocities were significantly lower in the patient groups compared to those in the controls (p=0.005 and p=0.002). Coronary flow velocity reserve was 1.65 ± 0.36 and 2.67 ± 0.81 in patients and healthy subjects, respectively (p < 0.001). The intima-media thickness was similar between the patients with non-alcoholic fatty liver disease and healthy subjects. The comparison of patients with non-alcoholic fatty liver and non-alcoholic steatohepatitis within the non-alcoholic fatty liver disease group with respect to coronary flow velocity reserve and intima-media thickness yielded no statistical differences., Conclusions: The present study showed that coronary flow velocity reserve, which establishes coronary microvascular and endothelial functions noninvasively, is significantly impaired in patients with non-alcoholic fatty liver disease. The impaired coronary flow velocity reserve-like early atherosclerotic changes may have value in the prediction of coronary artery disease in patients with non-alcoholic fatty liver disease.
- Published
- 2012
- Full Text
- View/download PDF
123. Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?
- Author
-
Yönal O, Hatemi G, and Kaymakoğlu S
- Subjects
- Enema, Humans, Suppositories, Time Factors, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Colitis, Ulcerative drug therapy, Mesalamine administration & dosage, Proctocolitis drug therapy
- Published
- 2012
- Full Text
- View/download PDF
124. Postprandial platelet-poor plasma 5-hydroxytryptamine concentrations during diarrhea and constipation periods of alternatingtype irritable bowel syndrome patients.
- Author
-
Sen F, Pinarbaşi B, Işsever H, Akyüz F, Mungan Z, and Kaymakoğlu S
- Subjects
- Adolescent, Adult, Blood Platelets metabolism, Case-Control Studies, Chromatography, High Pressure Liquid, Constipation physiopathology, Diarrhea physiopathology, Dietary Carbohydrates, Female, Humans, Irritable Bowel Syndrome physiopathology, Male, Middle Aged, Statistics, Nonparametric, Constipation blood, Diarrhea blood, Irritable Bowel Syndrome blood, Postprandial Period, Serotonin blood
- Abstract
Background/aims: Our aim was to measure concentrations of platelet-poor plasma 5-hydroxytryptamine and to assess any relationship with gastrointestinal symptomatology under fasting and fed conditions in alternating-type irritable bowel syndrome during both constipation and diarrhea periods separately. Results of the two periods were compared with each other as well as with the results of the controls., Methods: Nine patients with alternating diarrhea and constipation symptoms and 9 controls were enrolled. Serial plasma 5-hydroxytryptamine was measured for 1 hour under fasting and for 3 hour after a standard carbohydrate meal. Patients underwent the same measurements during constipation and diarrhea periods separately. Serum 5-hydroxytryptamine concentrations were determined by high-performance liquid chromatography. Symptomatology was assessed throughout the study., Results: Patients exhibited higher concentrations of platelet-poor plasma 5-hydroxytryptamine under fed conditions during diarrhea, especially at postprandial 30 minutes (p<0.05) compared with concentrations during constipation. Increases in postprandial plasma 5-hydroxytryptamine concentrations relative to fasting concentrations were also significantly higher during the diarrhea period than during constipation and in controls (p<0.05). Although there was no significant correlation between plasma 5-hydroxytryptamine concentrations and symptom scores, patients had worse postprandial symptomatology during diarrhea compared with controls (p<0.05)., Conclusions: Platelet-poor plasma 5-hydroxytryptamine concentrations after meal ingestion differ between constipation and diarrhea periods in alternating-type irritable bowel syndrome. Postprandial symptomatology is also more prominent during diarrhea. These results suggest that differences in plasma levels of serotonin between diarrhea and constipation may underlie the pathogenesis of alternating-type irritable bowel syndrome and could be involved in some aspects of symptomatology.
- Published
- 2011
- Full Text
- View/download PDF
125. Anticoagulant therapy and Budd-Chiari syndrome: is it successful?
- Author
-
Akyüz F, Cakaloğlu Y, Pinarbaşi B, Demir K, Akyüz U, Ozdil S, Beşişik F, Boztaş G, Mungan Z, and Kaymakoğlu S
- Subjects
- Adult, Budd-Chiari Syndrome mortality, Female, Humans, Male, Middle Aged, Anticoagulants therapeutic use, Budd-Chiari Syndrome drug therapy
- Abstract
Background/aims: Anticoagulant therapy is an accepted treatment for Budd-Chiari syndrome (BCS). However, the natural course of untreated patients is unclear. We aimed to evaluate the efficacy of anticoagulant therapy on survival in BCS., Methodology: Between 1995 and 2007, 45 patients diagnosed with BCS based on the clinical, biochemical, radiological and histological findings were retrospectively evaluated with respect to underlying disease, therapeutic interventions, complications and overall outcome. Complications and survival during the follow-up period were compared in between anticoagulant treated and untreated cases., Results: Mean patient age was 34.4 +/- 11.8 years and 46.7% (21) of them were male. Median followup time was 24 months (6-132); 8.9% of patients were diagnosed as acute, 31.1% as subacute and 60% as chronic BCS according to disease duration. Centrilobular necrosis was found in 16 of 36 biopsy performed patients. Etiological factors were detected in 60% of patients and 40% of them were cryptogenic. Twenty four of them received anticoagulant therapy, the remaining 21 were followed-up with supportive medical therapy. Five patients who had shunt operation were excluded for survival analyses. Complications were similar between treated and untreated cases (p>0.05). There was a positive correlation between survival and centrilobular necrosis (r=0.376, p=0.037). The mean survival periods were 95.5 months (%95 CI 73-117 months) and 72.5 months (%95 CI 42-103 months) in anticoagulant treated and untreated patients, respectively (p>0.246)., Conclusion: Most patients with BCS are admitted to hospital at the chronic stage and more than half of them have underlying thrombotic risk factor. In our study, no beneficial effects of anticoagulant therapy were observed on the survival and complications of liver disease.
- Published
- 2011
126. The quality of life in hemodialysis patients with chronic hepatitis C virus infection.
- Author
-
Akyüz F, Beşişik F, Pinarbaşi B, Demir K, Kaymakoğlu ST, Cakaloğlu Y, Sever MS, and Okten A
- Subjects
- Adult, Antiviral Agents therapeutic use, Anxiety psychology, Female, Health Surveys, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Male, Middle Aged, Motor Activity, Recombinant Proteins, Surveys and Questionnaires, Hepatitis C, Chronic psychology, Kidney Failure, Chronic psychology, Kidney Failure, Chronic surgery, Kidney Failure, Chronic therapy, Kidney Transplantation psychology, Quality of Life, Renal Dialysis psychology
- Abstract
Background/aims: We aimed to determine the quality of life in treated and untreated hemodialysis patients with chronic hepatitis C virus infection., Methods: Ninety-five chronic renal failure patients with positive antiHCV/HCV-RNA were enrolled in this prospective study. All patients were questioned using the Short Form-36 (SF-36) health survey to evaluate life quality after the treatment. Fifty-five (ALT>1.5 ULN) were treated with interferon-alpha-2b [3MU/tiw, sc, 6 (30 patients) and 12 (25 patients) months], and 40 (11 renal transplanted) were untreated. Fifteen patients had renal transplantation in a mean of 24.6+/-12.5 months after interferon-alpha treatment., Results: The mean age of the patients was 37+/-10 years, and 58 were male. The mean durations of hemodialysis and renal transplantation were 6.4+/-3.8 and 5.9+/-4.6 years, respectively. Interferon treatment had a negative effect on general health perception, physical activity and anxiety about the disease (p<0.05) when compared with the untreated patients. General health perception scores were positively slightly increased in interferon responder patients (p>0.05). General health and physical activity were better in transplanted patients than patients undergoing hemodialysis (p<0.05)., Conclusions: General health perception slightly increased positively in interferon responder patients. However, general health perception and physical activity were affected negatively by interferon treatment in the whole group analysis. Renal-transplanted patients have a better life quality compared with those on hemodialysis.
- Published
- 2009
- Full Text
- View/download PDF
127. Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey.
- Author
-
Cakaloğlu Y, Akyüz F, Bozaci M, Ibrişim D, Pinarbaşi B, Demir K, Kaymakoğlu S, Beşişik F, Badur S, and Okten A
- Subjects
- Adult, Alkaline Phosphatase blood, Aspartate Aminotransferases blood, Blood Donors statistics & numerical data, Comorbidity, DNA Virus Infections blood, DNA Virus Infections drug therapy, DNA, Viral genetics, DNA, Viral isolation & purification, Female, Genotype, Hepatitis B, Chronic blood, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic virology, Hepatitis C, Chronic blood, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Hepatitis D, Chronic blood, Hepatitis D, Chronic drug therapy, Hepatitis D, Chronic virology, Humans, Male, Prevalence, Retrospective Studies, Torque teno virus genetics, Treatment Outcome, Turkey epidemiology, gamma-Glutamyltransferase blood, DNA Virus Infections epidemiology, DNA Virus Infections virology, Hepatitis B, Chronic epidemiology, Hepatitis C, Chronic epidemiology, Hepatitis D, Chronic epidemiology, Torque teno virus isolation & purification
- Abstract
Background/aims: SEN viruses are transmitted parenterally and can cause post-transfusion hepatitis. The prevalence and clinical significance of SEN viruses have been investigated in patients with chronic hepatitis C and B but not in D. We aimed to determine the prevalence and clinical significance of SEN viruses- H in patients with chronic hepatitis C, B and delta in Turkey., Methods: SEN viruses-H was analyzed in 85 patients with chronic viral hepatitis (30 HCV, 30 HBV and 25 HDV) and 43 non-professional blood donors. HBV DNA, HCV RNA and HDV RNA were positive in patients with hepatitis B, C and D, respectively. SEN viruses-H DNA was detected by semi-nested polymerase chain reaction method (L2AS, C5S primer in first step, L2AS, D11 in second step) after extraction of DNA from sera (NucleoSpin blood; Macherey-Nagel GmbH & Co KG, Germany)., Results: SEN viruses-H DNA was found to be positive in 7/30 (23.3%), 10/30 (33.3%), 6/25 (24%), and 7/43 (16.2%) of patients with chronic C, B, and D hepatitis and healthy blood donors, respectively. There was no significant difference in clinical features and treatment response between SEN viruses- H-positive and -negative patients with chronic viral hepatitis., Conclusions: SEN viruses is more frequent in chronic hepatitis patients than in healthy blood donors. These results indicate that SEN viruses has no effect on the clinical course and treatment response of chronic viral hepatitis.
- Published
- 2008
128. A rare cause of hemosuccus pancreaticus: primary splenic artery aneurysm ruptured into pancreatic serous cystadenoma.
- Author
-
Pinarbaşi B, Poturoğlu S, Yanar H, Güven K, Akyüz F, Dizdaroğlu F, Güllüoğlu M, Taviloğlu K, Kaymakoğlu S, and Mungan Z
- Subjects
- Aneurysm, Ruptured diagnosis, Aneurysm, Ruptured surgery, Angiography, Celiac Artery diagnostic imaging, Cystadenoma, Serous diagnosis, Cystadenoma, Serous surgery, Female, Gastrointestinal Hemorrhage diagnosis, Gastrointestinal Hemorrhage surgery, Humans, Laparotomy, Middle Aged, Pancreatic Cyst diagnosis, Pancreatic Cyst surgery, Pancreatic Ducts diagnostic imaging, Pancreatic Ducts pathology, Pancreatic Ducts surgery, Rare Diseases, Rupture, Spontaneous complications, Rupture, Spontaneous diagnosis, Rupture, Spontaneous surgery, Splenectomy, Splenic Artery diagnostic imaging, Splenic Artery surgery, Tomography, X-Ray Computed, Aneurysm, Ruptured complications, Cystadenoma, Serous etiology, Gastrointestinal Hemorrhage etiology, Pancreatic Cyst etiology, Splenic Artery pathology
- Abstract
Hemosuccus pancreaticus is a rare clinical condition defined as bleeding into the pancreatic duct from a peripancreatic artery. We present here a 57-year-old woman admitted to our clinic with abdominal pain, tar-colored stool and confusion. Further investigations were done because of severe anemia. Abdominal computerized tomography revealed intraabdominal hematoma. Laparotomy was performed, which confirmed that intraabdominal haemorrhagia had occurred with the rupture of a splenic artery aneurysm into a pancreatic serous cystadenoma, which ruptured into the abdomen because of high pressure. This is an interesting case diagnosed with multidisciplinary approaches.
- Published
- 2008
129. Eosinophilic esophagitis: case report.
- Author
-
Mungan Z, Pinarbaşi B, and Kaymakoğlu S
- Subjects
- Adult, Androstadienes therapeutic use, Anti-Inflammatory Agents therapeutic use, Biopsy, Deglutition Disorders etiology, Eosinophilia drug therapy, Esophagitis drug therapy, Esophagoscopy, Esophagus pathology, Female, Fluticasone, Heartburn etiology, Humans, Male, Eosinophilia diagnosis, Esophagitis diagnosis
- Abstract
Eosinophilic esophagitis is an inflammatory condition of the esophagus characterized by eosinophilic infiltration. It is a condition mainly affecting children; the adult form has only recently gained recognition as a distinct entity. The major symptom among adults with eosinophilic esophagitis is dysphagia. It is often misdiagnosed as gastroesophageal reflux disease because of the similarity in symptoms. An endoscopic biopsy is required to distinguish between the conditions. The cause of eosinophilic esophagitis is poorly understood, but food allergy has been implicated. Topical steroids are the most effective and convenient method for the treatment of eosinophilic esophagitis in adults. The long-term prognosis of eosinophilic esophagitis is uncertain; however, data suggests a benign course. We herein present two eosinophilic esophagitis cases that were the first to be diagnosed in our clinic.
- Published
- 2007
130. The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension.
- Author
-
Akyüz F, Yekeler E, Kaymakoğlu S, Horasanli S, Ibrişim D, Demir K, Aksoy N, Poturoğlu S, Badur S, and Okten A
- Subjects
- Adult, Enzyme-Linked Immunosorbent Assay, Female, Humans, Hyaluronic Acid blood, Hypertension, Portal blood, Liver Cirrhosis blood, Liver Cirrhosis classification, Magnetic Resonance Imaging, Male, Middle Aged, Platelet Count, Prospective Studies, Spleen pathology, Thrombocytopenia blood, Hypertension, Portal complications, Liver Cirrhosis complications, Splenomegaly complications, Thrombocytopenia complications, Thrombopoietin blood
- Abstract
Background/aims: To determine the role of thrombopoietin and spleen volume in thrombocytopenia diagnosed in cirrhotic and noncirrhotic portal hypertensive patients., Methods: Seventy- four portal hypertensive patients (group 1: 28 noncirrhotic; group 2: 46 cirrhotic) were enrolled into this study. Spleen volume was measured by magnetic resonance imaging. Thrombopoietin and hyaluronic acid were detected by ELISA in sera., Results: Splenic volume was significantly higher in group 1 (1375+/-658.74 ml) than group 2 (981.78+/-512.39 ml). In group 1, thrombopoietin and hyaluronic acid levels were 76.6+/-30.39 pg/ml and 78.17+/-66.67 ng/ml, respectively. These values were significantly higher in group 2, at 99.89+/-38.5 pg/ml and 271.97+/-197.34 ng/ml, respectively (p<0.05). Platelet counts and thrombopoietin levels had a negative correlation with spleen volume in both groups (p<0.05). Serum thrombopoietin levels were not correlated with platelet counts in cirrhotic and noncirrhotic groups; however, thrombopoietin levels were negatively correlated with splenic volume in the whole group (p= 0.044, r= - 0.23). Although spleen volume was significantly larger in noncirrhotic patients, platelet counts were similar in both groups., Conclusions: This study confirms that splenic sequestration is the main factor in the thrombocytopenia in portal hypertensive patients. The balance of thrombopoietin production and degradation may be more important for platelet counts than decreasing synthesis.
- Published
- 2007
131. Evaluation of malignancy risk and endoscopic follow up in achalasia: case report.
- Author
-
Akyüz F, Ibrişim D, Balik E, Yonal O, Kaymakoğlu S, Buğra D, and Mungan Z
- Subjects
- Adult, Continuity of Patient Care, Esophageal Achalasia surgery, Esophageal Neoplasms prevention & control, Esophagectomy, Humans, Male, Risk Factors, Thoracotomy, Time Factors, Esophageal Achalasia epidemiology, Esophageal Neoplasms epidemiology, Gastroscopy
- Abstract
Achalasia is an esophageal motility disorder that is accepted as a risk factor for the development of cancer. Especially in megaesophagus, chronic irritation of foods and bacterial overgrowth may contribute to the formation of high-grade dysplasia and squamous cell carcinoma. We present a case of advanced stage achalasia with high-grade dysplasia detected three years after a cardiomyotomy operation. Cancer risk continues after surgical operation in achalasia, like in this case. In conclusion, endoscopic follow up is necessary for these patients even after surgical treatment.
- Published
- 2006
132. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication.
- Author
-
Duman DG, Bor S, Ozütemiz O, Sahin T, Oğuz D, Iştan F, Vural T, Sandkci M, Işksal F, Simşek I, Soytürk M, Arslan S, Sivri B, Soykan I, Temizkan A, Beşşk F, Kaymakoğlu S, and Kalayc C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Diarrhea chemically induced, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents adverse effects, Diarrhea prevention & control, Helicobacter Infections drug therapy, Helicobacter pylori, Probiotics therapeutic use, Saccharomyces
- Abstract
Background and Aim: Antibiotic-associated diarrhoea may develop during or following Helicobacter pylori eradication. We aimed to evaluate the efficacy and safety of Saccharomyces boulardii in preventing antibiotic-associated diarrhoea in patients receiving antibiotics for H. pylori eradication., Methods: In a multicentre prospective clinical trial, patients with peptic ulcer disease or non-ulcer dyspepsia were enrolled to receive clarithromycin, amoxicillin and omeprazole for H. pylori eradication for 14 days. These patients were then randomized to receive either S. boulardii 500 mg twice daily (treatment group) or no treatment (control group). The primary outcome measure was the development of diarrhoea during (treatment period) or within 4 weeks after treatment (follow-up period)., Results: Of the 389 patients that were enrolled, 376 completed the study. Within the treatment period, diarrhoea developed in 5.9% of patients in the treatment group and in 11.5% of patients in the control group (P = 0.049); and in the follow-up period, diarrhoea developed in 1.0% of patients in the treatment group and in 3.8% of patients in the control group (P = 0.09). Overall diarrhoea rates throughout the whole study period were 6.9% in the treatment group and 15.6% in the control group (P = 0.007). No significant difference was observed between the treatment and control groups in terms of adverse events., Conclusion: S. boulardii is an effective and safe treatment for prevention of antibiotic-associated diarrhoea when given concomitantly to patients receiving H. pylori eradication.
- Published
- 2005
- Full Text
- View/download PDF
133. Drug-induced hepatitis, drug-induced autoimmunity or classical autoimmune hepatitis: how can we differentiate?
- Author
-
Kaymakoğlu S
- Subjects
- Adult, Anemia, Hemolytic, Autoimmune chemically induced, Anemia, Hemolytic, Autoimmune diagnosis, Anemia, Hemolytic, Autoimmune immunology, Autoimmunity drug effects, Chemical and Drug Induced Liver Injury, Chronic immunology, Dydrogesterone pharmacology, Female, Hepatitis, Autoimmune immunology, Humans, Liver drug effects, Liver pathology, Progestins pharmacology, Chemical and Drug Induced Liver Injury, Chronic diagnosis, Chemical and Drug Induced Liver Injury, Chronic etiology, Dydrogesterone adverse effects, Hepatitis, Autoimmune diagnosis, Hepatitis, Autoimmune etiology, Progestins adverse effects
- Published
- 2004
134. Liver abscess as a rare complication of Crohn's disease: a case report.
- Author
-
Karaca C, Pinarbaşi B, Danalioğlu A, Akyüz F, Kaymakoğlu S, Ozdil S, Boztaş G, and Mungan Z
- Subjects
- Anti-Bacterial Agents, Combined Modality Therapy, Crohn Disease diagnosis, Drainage methods, Drug Therapy, Combination therapeutic use, Humans, Liver Abscess diagnosis, Male, Middle Aged, Prognosis, Rare Diseases, Risk Assessment, Severity of Illness Index, Streptococcal Infections diagnosis, Streptococcus pyogenes isolation & purification, Tomography, X-Ray Computed, Treatment Outcome, Ultrasonography, Doppler, Crohn Disease complications, Liver Abscess etiology, Liver Abscess therapy, Streptococcal Infections etiology, Streptococcal Infections therapy
- Abstract
Pyogenic liver abscess is a rarely seen extraintestinal complication of Crohn's disease. It has different features from other liver abscesses. Its clinical and laboratory findings are not specific and mimic the reactivation of Crohn's disease and diagnosis can be delayed. The radiological methods are very useful in diagnosis and treatment of liver abscess. In this paper, we present a patient with pyogenic liver abscess which developed in the course of Crohn's disease.
- Published
- 2004
135. Alverine induced toxic hepatitis: a case report.
- Author
-
Durakoğlu Z, Boztaş G, Sezgil A, Kaymakoğlu S, Dinçer D, Ozdil S, Beşişik F, Mungan Z, and Okten A
- Abstract
Drug-induced hepatotoxicity is an important cause of hepatocellular injury. Hepatic necrosis may range from asymptomatic elevations in transaminases to fulminant hepatic failure and death. Alverine is an antispasmodic drug which is especially used in patients with irritable bowel syndrome. Only a few cases of alverine associated hepatotoxicity have been reported previously. We present the case of a patient with alverine induced hepatotoxicity and cholestasis, which has only seldomly been reported in the literature.
- Published
- 2002
136. Efficacy of cyclosporin in severe ulcerative colitis attack.
- Author
-
Danalioğlu A, Kaymakoğlu S, Mungan Z, Karaca C, Demir K, Durakoğlu Z, Beşişik F, Boztaş G, Cakaloğlu Y, and Okten A
- Abstract
Background/aims: Cyclosporin-A is used as a alternative medical therapy in steroid resistant ulcerative colitis with severe activity. In spite of its known efficacy, the long term effects of are not entirely clear., Methods: The records of 13 steroid resistant patients treated with cyclosporin-A were retrospectively assessed. Cyclosporin-A had been prescribed orally at a dose of 8 mg/kg/day in four patients and intravenously, 4mg/kg/day in nine patients. Intravenous therapy was changed to oral therapy after one week and patients also received 5-ASA and azathioprine. Steroid treatment was tapered., Results: Ten patients responded to treatment in a mean of nine days (range: 2-30 days). Three patients who did not respond underwent total colectomy on day seven, 11 and 19 of therapy. The 10 patients who initially responded received the drug for an average of 4.9 months; four of these relapsed during and one relapsed soon after discontinuation of therapy. Four of the five patients who relapsed underwent colectomy and the one patient who did not accept surgical intervention continued medical therapy. The remaining five patients (38% of the total group; 50% of the patients who initially responded) remained in remission at the end of an average 17 month follow up period., Conclusions: Cyclosporin-A therapy in severe ulcerative colitis that is resistant to steroids, provides initial remission in 80% of patients and allows 40% to retain their colon for one year.
- Published
- 2002
137. The prevalence of manifest and latent celiac disease in type 1 diabetes mellitus.
- Author
-
Güvenç S, Kaymakoğlu S, Gürel N, Karşidağ K, Demir K, Dinçer D, Kekik C, Salman S, Yilmaz T, Beşişik F, and Cakaloğlu Y
- Abstract
Background/aims: Celiac disease and type 1 diabetes mellitus are both autoimmune diseases which have a common genetic predisposition. The aim of this study was to determine the prevalence of manifest and latent celiac disease in type 1 diabetic patients., Methods: Anti-endomysium IgA was tested by indirect immunofluorescence using sections of human umbilical cord for screening in 100 adult patients with type 1 diabetes mellitus and in 80 age and sex matched controls with no known disease. Distal duodenal biopsy, human leukocyte antigen typing, urinary D-xylose excretion test, stool analysis, biochemistry profile, blood counts, serum ferritin level and small intestinal radiography were performed in anti-endomysium IgA positive cases. Small bowel biopsy specimens consistent with celiac disease were defined as manifest celiac disease, while positive antiendomysium IgA and normal intestinal histology with the presence of human leukocyte antigen class II antigens consistent with the disease were defined as latent celiac disease., Results: Anti-endomysium IgA was positive in eight diabetic patients, while it was negative in all controls. Celiac disease was found in a total of six (6%) patients, four with manifest and two with latent disease. Only one patient had symptoms., Conclusions: The prevalence of celiac disease is increased in patients with type 1 diabetes mellitus. Since many patients may be asymptomatic, it is suggested that all diabetic patients should be screened for this disease.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.